Analyst Price Targets — IMRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 6, 2026 10:06 am | — | UBS | $14.00 | $4.39 | TheFly | Immuneering initiated with a Buy at H.C. Wainwright |
| July 8, 2026 10:51 am | Li Watsek | Cantor Fitzgerald | $17.00 | $5.10 | TheFly | Immuneering initiated with an Overweight at Cantor Fitzgerald |
| March 9, 2026 10:50 am | — | Piper Sandler | $12.00 | $5.62 | TheFly | Immuneering price target lowered to $12 from $13 at Piper Sandler |
| October 29, 2025 12:51 pm | — | Mizuho Securities | $12.00 | $6.49 | TheFly | Immuneering price target raised to $12 from $10 at Mizuho |
| September 25, 2025 12:57 pm | Jay Olson | Oppenheimer | $30.00 | $9.23 | TheFly | Immuneering price target raised to $30 from $21 at Oppenheimer |
| April 2, 2024 6:36 am | Graig Suvannavejh | Mizuho Securities | $8.00 | $2.75 | StreetInsider | Immuneering Corporation (IMRX) PT Lowered to $8 at Mizuho, 'maintain our favorable view on IMRX's innovative approach' |
| March 15, 2024 6:26 am | Michael Yee | Jefferies | $3.00 | $1.91 | StreetInsider | Jefferies Downgrades Immuneering Corporation (IMRX) to Hold |
| September 30, 2022 12:16 pm | Swapnil Malekar | Piper Sandler | $41.00 | $15.50 | TheFly | Immuneering transitions to clinical stage with IND approval, says Piper Sandler |
| July 9, 2022 6:13 am | Geulah Livshits | Loop Capital Markets | $18.00 | $7.28 | Pulse 2.0 | Immuneering (IMRX) Stock: Why It Surged 28.85% |
Latest News for IMRX
- For patients with second-line (2L) metastatic pancreatic cancer, today's FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic cancer, Immuneering's atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 – - 17.3-month median overall survival previously reported from Immuneering's Phase 2a study of atebimetinib plus…
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 - - Phase 3 MAPKeeper 301 trial is underway, with patients being dosed and over 30 study locations posted to date - - Peer-reviewed publication in Cancer Research details atebimetinib's broad, durable preclinical…
Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to…
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors -
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMRX.
U.S. House Trading
No House trades found for IMRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.